Topical glaucoma medications: Clinical implications for the ocular surface
Research output: Contribution to journal › Review › Research › peer-review
Standard
Topical glaucoma medications : Clinical implications for the ocular surface. / Fineide, Fredrik; Lagali, Neil; Adil, Muhammed Yasin; Arita, Reiko; Kolko, Miriam; Vehof, Jelle; Utheim, Tor P.
In: Ocular Surface, Vol. 26, 2022, p. 19-49.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Topical glaucoma medications
T2 - Clinical implications for the ocular surface
AU - Fineide, Fredrik
AU - Lagali, Neil
AU - Adil, Muhammed Yasin
AU - Arita, Reiko
AU - Kolko, Miriam
AU - Vehof, Jelle
AU - Utheim, Tor P.
N1 - Funding Information: Tor Paaske Utheim is co-founder and co-owner of The Norwegian dry eye clinic and the Clinic of eye health, Oslo, Norway, which delivers talks for and/or receives financial support from the following: ABIGO, Alcon, Allergan, AMWO, Bausc'h&Lomb, Bayer, European school for advanced studies in ophthalmology, InnZ Medical, Medilens Nordic, Medistim, Novartis, Santen, Specsavers, Shire Pharmaceuticals and Thea Laboratories. He has served on the global scientific advisory board for Novartis and Alcon as well as the European advisory board for Shire Pharmaceuticals. Utheim is the Norwegian Global Ambassador for Tear Film and Ocular Surface Society (TFOS), a Board Member of the International Ocular Surface Society, an International Member of the Japanese Lid and Meibomian gland working group (LIME), a Consultant at the Norwegian Association for the Blind and Partially Sighted, the President of the Oslo Society of ophthalmology, and the Editor-in-Chief of Oftalmolog, an eye journal distributed to all eye doctors in the Nordic region since 1980. Besides publishing articles of presumed interest to our readers, Oftalmolog publishes advertisements from pharmaceutical companies, companies selling ophthalmological equipment, and associations organizing conferences and events in ophthalmology. For more information, visit: oftalmolog.com .
PY - 2022
Y1 - 2022
N2 - Glaucoma is a leading cause of irreversible blindness. The use of topical eye drops to reduce intraocular pressure remains the mainstay treatment. These eye drops frequently contain preservatives designed to ensure sterility of the compound. A growing number of clinical and experimental studies report the detrimental effects of not only these preservatives but also the active pharmaceutical compounds on the ocular surface, with resultant tear film instability and dry eye disease. Herein, we critically appraise the published literature exploring the effects of preservatives and pharmaceutical compounds on the ocular surface.
AB - Glaucoma is a leading cause of irreversible blindness. The use of topical eye drops to reduce intraocular pressure remains the mainstay treatment. These eye drops frequently contain preservatives designed to ensure sterility of the compound. A growing number of clinical and experimental studies report the detrimental effects of not only these preservatives but also the active pharmaceutical compounds on the ocular surface, with resultant tear film instability and dry eye disease. Herein, we critically appraise the published literature exploring the effects of preservatives and pharmaceutical compounds on the ocular surface.
KW - Dry eye disease
KW - Eyedrops
KW - Glaucoma
KW - Meibomian gland dysfunction
KW - Topical medications
U2 - 10.1016/j.jtos.2022.07.007
DO - 10.1016/j.jtos.2022.07.007
M3 - Review
C2 - 35921942
AN - SCOPUS:85135711997
VL - 26
SP - 19
EP - 49
JO - The Ocular Surface
JF - The Ocular Surface
SN - 1542-0124
ER -
ID: 318205833